[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Societa Italiana di Pneumologia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100574171","italian-registry-of-pneumonia-in-immunocompromised-patients-argonaut-100574171",false,"NCT06755814","ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)","Community-acquired Pneumonia in Immunosuppressed Adult Patients: Observational, Perspective Study, ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)","ARGONAUT","Inclusion Criteria:\n\nHospitalized patients with a confirmed diagnosis of Community-Acquired Pneumonia (CAP) characterized by at least one of the following risk factors for immunosuppression:\n\n* AIDS,\n* Aplastic anemia;\n* Asplenia;\n* Hematologic malignancy (e.g., lymphoma\u002Facute or chronic myeloid leukemia\u002Fmultiple myeloma);\n* Chemotherapy within the last 3 months;\n* Neutropenia defined as a white blood cell count less than 500\u002FdL on a complete blood count;\n* Use of biologics (including trastuzumab and therapy for autoimmune diseases (e.g., anti-TNF α), prescribed within the last 6 months before hospital admission;\n* Solid organ transplant;\n* Bone marrow transplant;\n* Chronic oral steroid use (\\>10 mg\u002Fday prednisone or equivalent ≥3 months before accessing the ED, or cumulative dose \\> 600 mg prednisone);\n* Use of corticosteroid therapy with a dose ≥ 20 mg prednisone or equivalent ≥14 days or cumulative dose \\> 600 mg prednisone;\n* Active malignancy;\n* Malignancy within one year of pneumonia (excluding patients with localized skin cancer or early-stage malignancy);\n* Lung malignancy with neutropenia\u002Fchemotherapy;\n* Other solid malignancy with neutropenia\u002Fchemotherapy;\n* Other immunodeficiency (including congenital\u002Fgenetic immunosuppression and immunosuppressive therapy secondary to hematologic malignancy or solid malignancy);\n* Primary immunodeficiency.\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":20,"type":21},1298,"ESTIMATED","OBSERVATIONAL","This multicentric, prospective study aims at:\n\nevaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical, microbiological and genetic analysis on collected samples.",[25],"Community Acquired Pneumonia (CAP)",[27,28,29,30,31],"CAP","Immunosuppressed","Immunocompromised","Pneumonia","community-acquired pneumonia;","RECRUITING","2025-11-14",{"date":35,"type":36},"2025-11-18","ACTUAL",{"date":38,"type":36},"2025-08-11",{"date":40,"type":21},"2028-12",{"name":42,"class":43},"Societa Italiana di Pneumologia","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":56,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":44},"100423666","mani-real-life-perspective-observatory-100423666","NCT04796844","MANI Real-life Perspective Observatory","Mild\u002FModerate Asthma Network of Italy Observatory","MANI","Inclusion Criteria:\n\n* Adult patients\n* Asthma diagnosis according GINA 2020 algorithm (Annex 1)\n* Patients enrolled in other previous or ongoing observational studies\n\nExclusion Criteria:\n\n* Severe asthma patients according International ERS\u002FATS guidelines on definition, evaluation and treatment of severe asthma. \\[Chung KF et al. European Respiratory Journal Feb 2014, 43 (2) 343-373; DOI: 10.1183\u002F09031936.00202013 (Annex 2)\\]\n* Subjects are excluded from this cohort if they exhibit interstitial lung diseases, pulmonary neoplasms, current lung infections, immunological disorders leading to the use of immunosuppressants or continuous treatment with oral steroids.","99 Years",{"count":55,"type":21},20000,"10 Years","The purpose of this registry aims is to collect a large number of patients with mild and moderate asthma in a real-word conditions for a perspective observation of epidemiological evolution of the disease in relation to the therapeutic interventions available currently and in the near future.",[59,60,61],"Asthma","Mild Asthma","Moderate Asthma",[59,63,64,65,66,67],"Adult","Cluster","Cohort study","Italy","Prospective","2023-11-22",{"date":70,"type":36},"2023-11-28",{"date":72,"type":36},"2021-05-01",{"date":74,"type":21},"2032-11",{"name":42,"class":43},""]